Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
about
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled studySurface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasionInvolvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivoThe common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Characterization of two novel cryptococcal mannoproteins recognized by immune sera.Unraveling the novel structure and biosynthetic pathway of O-linked glycans in the Golgi apparatus of the human pathogenic yeast Cryptococcus neoformans.Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system.Paradoxical Immune Responses in Non-HIV Cryptococcal MeningitisIsolation and purification of antigenic components of CryptococcusThe relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.Preventative and therapeutic vaccines for fungal infections: from concept to implementation.Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotidesRole of the mannose receptor in a murine model of Cryptococcus neoformans infectionLoss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformansGlycoconjugates and polysaccharides of fungal cell wall and activation of immune systemProtective immunity against cryptococcus neoformans infection.A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.The intracellular life of Cryptococcus neoformans.Pharmacotherapy of cryptococcosis.Macrophage Cryptococcus interactions: an update.Cryptococcus antigens and immune responses: implications for a vaccine.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.Immunotherapy of Fungal Infections.Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii.A Call to Arms: Quest for a Cryptococcal Vaccine.A Predicted Mannoprotein Participates in Cryptococcus gattii Capsular Structure.
P2860
Q24604509-DF10E9B4-1696-46C0-9EB8-B65B19708202Q28475575-509337B9-D416-4475-AE61-4766B9EA4087Q28512482-8C508679-D0F4-4520-AFCD-F900E2817605Q34099803-6AB776A8-5176-4EDA-AE81-10FBA16189D3Q34111740-08170707-1127-412F-8D8C-4729CE47C4C4Q35121366-61AC5DA0-B6C4-4751-AEE0-C82B8E3971D5Q35217511-7E9852BE-23A3-43C4-B25D-3F6266B5A197Q35645083-AEE6F2CC-31BC-43D8-8EC7-2A5AD4B64C17Q35813386-A3E9387B-B95D-4437-AFA5-EB7BA21697C7Q35913526-14EDB057-7435-4F8A-B789-24F0CD2AEFF1Q35987809-F2988D5F-8A03-4C0F-9B5A-92FD1A1C9B95Q36431583-6B64FDF2-5D02-45A2-AAD2-B71D7586267FQ36544402-CE61019C-1F9A-4CF6-B7F8-74CCBA0FB70CQ36710580-A655BA6E-764E-4B94-9617-28DA1517FB26Q37033075-F0E79DE1-12EB-42EB-942D-ACB3FE20E687Q37159154-2CFA1B72-C578-48F0-9FD6-24AAD57BE8B3Q37181729-AA10939D-9758-4675-8B55-CA69B6FF65BEQ37367575-2F2A54D5-3DF8-4069-B00E-66851B08B4CEQ37452401-B4410274-5F39-4392-8FAA-EBCD67D5E65CQ37587230-C267C908-3F9F-4C9F-9A0E-EFD601FECC3FQ37645657-4187E956-CE4D-4587-94EE-BED3D277F1EDQ38155197-E12005E2-A398-4850-BA9C-3AE47EF8B806Q38264288-3A51893C-B054-47CB-A159-BBBAE4653682Q38635409-A2AA4556-3214-49D6-AC33-2BF04C92E811Q43888767-8144BD42-B797-4CD9-8CFC-EF189C036B64Q50149203-B1F7A839-E06B-45DD-8753-7BFF118A6B32Q55220364-1FDEBBBF-7220-4FD6-A6B5-DC27F21C761F
P2860
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@ast
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@en
type
label
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@ast
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@en
prefLabel
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@ast
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@en
P2093
P2860
P1476
Protective efficacy of antigenic fractions in mouse models of cryptococcosis.
@en
P2093
James B Rottman
Lauren E Yauch
Michael K Mansour
Stuart M Levitz
P2860
P304
P356
10.1128/IAI.72.3.1746-1754.2004
P407
P577
2004-03-01T00:00:00Z